6/21/2011

Karen Midthun, who will preside over a public hearing on Genentech's cancer drug Avastin next week, rejected an FDA proposal that would require witnesses to disclose financial relationships with the drug’s maker or competitors. Roche, Genentech's parent, is appealing the agency's plan to revoke Avastin's approval for breast cancer. The FDA may cross-examine witnesses if it "is concerned that there are additional financial interests that affect the credibility of the opinions advanced by the Genentech presenters," Midthun said.

Related Summaries